Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 07, 2022, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 07, 2022, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg".